Abstract
Aim: The aim of this study is to assess the utility of the sPESi (simplified pulmonary embolism severity index) to predict all-cause mortality related risk only in patients with high sPESi score due to cancer diagnosis.
Methods: We performed a retrospective analysis of high sPESi score patients. Outpatients and high-risk patients were excluded from the study. Two cohorts were created as patients with cancer and without cancer. We divided the cancer cohort into 2 groups; patients with sPESi score=1 and patients with sPESI score ≥ 2. Patients with sPESi score=1 did not have an additional sPESi score component other than cancer.
Results:
| Median age |
n=97 72 (25–95) |
Cancer cohort (n=45) 56 (28-89) |
Non-cancer cohort (n=52) 79.5 (25-95) |
|
İntermediate low-risk İntermediate high-risk |
57.7% 42.3% |
64.4% 35.6% |
51.9% 48.1% |
|
Cancer Age>80 Pulse rate ≥110 b.p.m. Systolic BP <100 mmHg Arterial oxyhaemoglobin saturation <90% Chronic cardiopulmonary diseases |
53.6% 28.9% 35.1% 11.3% 33% 42.3% |
100% 13.3% 37.8% 15.6% 22.2% 40% |
0 42.3% 32.7% 5.8% 42.3% 44.2% |
| sPESi score | ≥1 (%100) | =1 (24.4%) ≥2 (75.6%) | =1 (55.8%) ≥2 (44.2%) |
| All-cause mortality 30 day | 11.3% | 11.1% | 11.5% |
This study provides an idea to reevaluate the role of cancer in sPESi.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA505.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
